ClinicalTrials.gg
CompletedNCT05714254Updated Jan 5, 2024

Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy Volunteers

A Phase 1 interventional study of MEDI0618 and Placebo in Chronic Pain, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies in Chronic Pain with a site in Germany — 11 open to participants now, 14 under way, 8 of them phase 3. Chronic Pain · Germany.

Enrollment
42nd of 50
36 · median 91
Started
2022
with 5 others
Phase 1
4 of 70
none open now
Registered
57th of 70
by date
Lead sponsor
3 of 70
AstraZeneca

Among the 70 studies in Chronic Pain with a site in Germany, this one is the 42nd largest by enrollment of the 50 interventional ones that give a count, is one of 6 that started in 2022, is one of 4 in phase 1, and was the 57th registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

11 of the 70 studies in Chronic Pain with a site in Germany are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Chronic Pain with a site in Germany, or all of them as a file.
02

Study summary

This is a single centre, randomised, double-blind, placebo-controlled, multiple ascending dose study of MEDI0618 in healthy male and female volunteers.

Subjects will receive MEDI0618 or placebo administered by intravenous infusion or subcutaneous injection.

Safety, tolerability and pharmacokinetics of multiple ascending doses of MEDI0618 will be assessed.

03

Conditions studied

  • Chronic Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy men and women of non-child bearing potential
  • Aged 18 to 50 years, inclusive
  • Weigh more than 50 kg
  • between 18 to 30 kg/m2
  • Healthy, in the opinion of the Principal Investigator
  • Able to understand and comply with the protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical study with a study drug within 5 half-lives of that study drug or within 3 months prior to screening, whichever is longer
  • Donation of blood or plasma within 2 months prior to screening and until after the final follow-up visit
  • Poor venous access
  • History of severe allergy/ reactions or history of hypersensitivity to immunisations, immunoglobulins or biologics
  • Prescence of any illness, such as cardiovascular, neurological, pulmonary, hepatic, renal, metabolic, gastro-intestinal, urologic, immunologic or endocrine disease or disorder
  • History of cancer within 5 years of screening
  • History of drug abuse
  • Use of prescriptions or non-prescription medicines within 7 days or 5 half-lives, whichever is longer, prior to administration of study treatments
  • Any clinical abnormality on complete physical examination, vitals signs, or clinical laboratory test results at screening or between screening and randomisation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    MEDI0618

    A human immunoglobulin antibody to the Protease Activated Receptor 2 (PAR2)

    Drug: MEDI0618

  • Placebo comparator
    Placebo

    Histidine/histidine HCl, sucrose and polysorbate

    Drug: Placebo

Interventions

  • Four doses of 100 mg IV, 200 mg IV or 200 mg SC MEDI0618 administered once every two weeks.

    Also known as: Protease-Activated Receptor 2 Antagonist

  • DrugPlacebo

    Four doses of IV placebo or SC placebo administered once every two weeks.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    To characterise the safety and tolerability of MEDI0618 administered IV or SC

    Time frame: From Screening, Day 1 to Day 113

  2. Incidence of abnormal vital signs

    To characterise the safety and tolerability of MEDI0618 administered IV or SC

    Time frame: From Screening, Day 1 to Day 113

  3. Incidence of abnormal laboratory parameters

    To characterise the safety and tolerability of MEDI0618 administered IV or SC

    Time frame: Day -1, Day 15, Day 29, Day 43, Day 57, Day 71, Day 99, Day 113

Secondary outcomes

  1. Time to maximum observed plasma concentration (Tmax) of MEDI0618

    To characterise the pharmacokinetic (PK) profile of MEDI0618 administered IV or SC

    Time frame: Day 1 to Day 113

  2. Maximum observed plasma concentration (Cmax) of MEDI0618

    To characterise the pharmacokinetic (PK) profile of MEDI0618 administered IV or SC

    Time frame: Day 1 to Day 113

  3. Area under plasma concentration-time curve over dosing interval (AUC[tau]) of MEDI0618

    To characterise the pharmacokinetic (PK) profile of MEDI0618 administered IV or SC

    Time frame: Day 1 to Day 113

  4. Pre-dose trough concentration (Ctrough) of MEDI0618

    To characterise the pharmacokinetic (PK) profile of MEDI0618 administered IV or SC

    Time frame: Day 1 to Day 113

  5. The volume of plasma cleared of drug per unit time (CL) of MEDI0618

    To characterise the pharmacokinetic (PK) profile of MEDI0618 administered IV or SC

    Time frame: Day 1 to Day 113

  6. Anti-drug antibodies (ADA)

    To characterise the immunogenicity of MEDI0618 administered IV or SC

    Time frame: Day 1, Day 8, Day 29, Day 43, Day 57, Day 71, Day 99, Day 113

07

Study locations

1 site
  • Research Site
    Berlin, 10117, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Dec 2023, 12 months.

Of 27 industry-sponsored phase 1 interventional studies under Chronic Pain, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 12 months is above that.

Counting every sponsor, half of 60 studies reached it within 12 months; a quarter within 6 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2022
First posted
Feb 6, 2023
StartActual
Dec 12, 2022
Primary completionActual
Dec 12, 2023
CompletionActual
Dec 12, 2023
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05714254
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 6, 2023
Start date
Dec 12, 2022
Primary completion
Dec 12, 2023
Completion
Dec 12, 2023
Last update
Jan 5, 2024

Study contacts

Stanislav Ignatenko
principal investigator · Charite Research Organisation, Berlin Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MEDI0618

Start the discussion